Silverarc Capital Management, LLC Affimed N.V. Transaction History

Silverarc Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $253,367 - $333,576	-47,182 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $858,744 - $1.16 Million	-155,008 Reduced 76.66%	47,182 $292,000
Q2 2021 Aug 16, 2021	SELL	$7.78 - $11.4 $2.34 Million - $3.42 Million	-300,140 Reduced 59.75%	202,190 $1.72 Million
Q1 2021 May 18, 2021	BUY	$5.12 - $8.48 $523,929 - $867,758	102,330 Added 25.58%	502,330 $3.97 Million
Q4 2020 Feb 16, 2021	BUY	$3.16 - $7.03 $1.26 Million - $2.81 Million	400,000 New	400,000 $2.33 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.